A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Clinical trial NCT05562830 · RECRUITING
Trial details
- NCT number
- NCT05562830
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-16
- Primary completion
- 2029-02-26
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.